company background image
MOC

Molecure WSE:MOC Stock Report

Last Price

zł14.40

Market Cap

zł202.0m

7D

-0.6%

1Y

-67.1%

Updated

29 Sep, 2022

Data

Company Financials
MOC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MOC Stock Overview

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland.

Molecure Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Molecure
Historical stock prices
Current Share Pricezł14.40
52 Week Highzł44.45
52 Week Lowzł12.04
Beta2.79
1 Month Change-8.86%
3 Month Change-8.28%
1 Year Change-67.12%
3 Year Change20.50%
5 Year Changen/a
Change since IPO-50.35%

Recent News & Updates

Aug 16
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

MOCPL PharmaceuticalsPL Market
7D-0.6%0.8%-7.9%
1Y-67.1%-1.8%-35.7%

Return vs Industry: MOC underperformed the Polish Pharmaceuticals industry which returned -0.4% over the past year.

Return vs Market: MOC underperformed the Polish Market which returned -33.1% over the past year.

Price Volatility

Is MOC's price volatile compared to industry and market?
MOC volatility
MOC Average Weekly Movement9.0%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement6.1%
10% most volatile stocks in PL Market11.7%
10% least volatile stocks in PL Market3.8%

Stable Share Price: MOC is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: MOC's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

FoundedEmployeesCEOWebsite
201294Marcin Szumowskihttps://molecure.com

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022.

Molecure Fundamentals Summary

How do Molecure's earnings and revenue compare to its market cap?
MOC fundamental statistics
Market Capzł202.03m
Earnings (TTM)-zł14.76m
Revenue (TTM)zł1.95m

103.7x

P/S Ratio

-13.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MOC income statement (TTM)
Revenuezł1.95m
Cost of Revenuezł2.20m
Gross Profit-zł247.17k
Other Expenseszł14.51m
Earnings-zł14.76m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Sep 29, 2022

Earnings per share (EPS)-1.05
Gross Margin-12.69%
Net Profit Margin-757.47%
Debt/Equity Ratio0%

How did MOC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MOC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOC?

Other financial metrics that can be useful for relative valuation.

MOC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue58.4x
Enterprise Value/EBITDA-8.5x
PEG Ration/a

Price to Book Ratio vs Peers

How does MOC's PB Ratio compare to its peers?

MOC PB Ratio vs Peers
The above table shows the PB ratio for MOC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average11.5x
CLN Celon Pharma
1.2x-33.5%zł663.4m
BGD Biogened
1.1xn/azł34.6m
CBD Cannabis Poland
41.5xn/azł6.4m
GX1 genXone
2.2xn/azł44.7m
MOC Molecure
1.5xn/azł202.0m

Price-To-Book vs Peers: MOC is good value based on its Price-To-Book Ratio (1.5x) compared to the peer average (11.5x).


Price to Earnings Ratio vs Industry

How does MOC's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

Price-To-Book vs Industry: MOC is good value based on its Price-To-Book Ratio (1.5x) compared to the European Pharmaceuticals industry average (2x)


Price to Book Ratio vs Fair Ratio

What is MOC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MOC's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of MOC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MOC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MOC's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Molecure forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


12.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Molecure has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Molecure's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Molecure competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Molecure performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


48.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MOC is currently unprofitable.

Growing Profit Margin: MOC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MOC is unprofitable, but has reduced losses over the past 5 years at a rate of 48.5% per year.

Accelerating Growth: Unable to compare MOC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MOC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.1%).


Return on Equity

High ROE: MOC has a negative Return on Equity (-10.69%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Molecure's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: MOC's short term assets (PLN108.5M) exceed its short term liabilities (PLN5.3M).

Long Term Liabilities: MOC's short term assets (PLN108.5M) exceed its long term liabilities (PLN4.3M).


Debt to Equity History and Analysis

Debt Level: MOC is debt free.

Reducing Debt: MOC had no debt 5 years ago.

Debt Coverage: MOC has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MOC has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Molecure current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Molecure Dividend Yield vs Market
How does Molecure dividend yield compare to the market?
SegmentDividend Yield
Company (Molecure)n/a
Market Bottom 25% (PL)3.1%
Market Top 25% (PL)9.6%
Industry Average (Pharmaceuticals)2.9%
Analyst forecast in 3 Years (Molecure)n/a

Notable Dividend: Unable to evaluate MOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MOC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MOC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MOC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MOC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Marcin Szumowski

no data

Tenure

zł388,484

Compensation

Mr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...


Leadership Team

Experienced Management: MOC's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: MOC's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of MOC?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders93,0330.7%
Private Companies1,051,0007.5%
Institutions2,218,02815.8%
Hedge Funds4,135,00029.5%
General Public6,532,93946.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 17 shareholders own 53.44% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
29.47%
Black Forest Capital, LLC
4,135,000PLN59.5m0%78.65%
7.21%
Szumowski Investments SKA
1,011,000PLN14.6m0%no data
6.02%
NN Investment Partners Holdings N.V.
845,000PLN12.2m0%0.01%
3.66%
Norges Bank Investment Management
513,517PLN7.4m0%no data
2.76%
Esaliens TFI S.A.
386,750PLN5.6m0%0.56%
2.59%
Allianz Asset Management AG
363,700PLN5.2m32.43%no data
0.41%
Marcin Szumowski
58,000PLN835.2k0%no data
0.38%
Metlife Towarzystwo Funduszy Inwestycyjnych S.A.
53,308PLN767.6k-0.46%0.04%
0.29%
FTF Columbus S.A.
40,000PLN576.0k0%no data
0.25%
Slawomir Broniarek
34,506PLN496.9k0%no data
0.2%
MetLife Powszechne Towarzystwo Emerytalne S.A.
27,893PLN401.7k0%0.01%
0.12%
BNPP Asset Management Holding
17,264PLN248.6k-48.32%no data
0.04%
Rockbridge TFI S.A.
5,639PLN81.2k-30.96%0.03%
0.02%
Towarzystwo Funduszy Inwestycyjnych BGZ BNP Paribas S.A.
2,783PLN40.1k-58.3%0.03%
0.013%
AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A.
1,774PLN25.5k0%no data
0.0038%
Rafal Kaminski
527PLN7.6k0%no data
0.0029%
Towarzystwo Funduszy Inwestycyjnych PZU SA
400PLN5.8k0%no data

Company Information

Molecure S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Molecure S.A.
  • Ticker: MOC
  • Exchange: WSE
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: zł202.032m
  • Shares outstanding: 14.03m
  • Website: https://molecure.com

Number of Employees


Location

  • Molecure S.A.
  • Zwirki i Wigury 101
  • Warsaw
  • 02-089
  • Poland


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MOCWSE (Warsaw Stock Exchange)YesBearer SharesPLPLNApr 2018
1B1DB (Deutsche Boerse AG)YesBearer SharesDEEURApr 2018

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/29 00:00
End of Day Share Price2022/09/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.